ADORA2A and neurodegenerative disease: Antagonists of the A2AR are promising to combat neurodegenerative diseases due to evidence from different laboratories in preclinical research in different animal models of neurodegeneration and because a first-in-class A2AR antagonist, istradefylline, has been approved in Japan and the US for human use.